Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Gail J. Roboz, Janelle Meyer, Winny Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael R. Savona

Blood (2023) 142 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2023-178024

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Pankit Vachhani, Abdulraheem Yacoub, Elie Traer, Lina Benajiba, Francesco Passamonti, Ashwin Kishtagari, Mojtaba Akhtari, James McCloskey, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas

Blood (2023) 142 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2023-178725

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Maher Albitar, Hong Zhang, Andrew Ip, Gustavo A. Rivero, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2023-187606

Published: 2023

Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy

Blood (2023) 142 (Supplement 1): 3654.

https://doi.org/10.1182/blood-2023-187041

Published: 2023

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Results of Cynk-001-AML-001: A Phase I Multi-Dose Study Evaluating the Safety, Tolerability, and Persistence of Cynk-001 in Adults with De Novo or Secondary Acute Myeloid Leukemia in Morphologic Complete Remission with Minimal Residual Disease or Relapsed/Refractory AML

James McCloskey, Hongtao Liu, Daniel N. Egan, Jesus G. Berdeja, Stephanie B. Tsai, Adrian Kilcoyne, Cherie Daly, Sharmila Koppisetti, Ramji Krishnan, Robert Hariri, Eunice S Wang

Blood (2023) 142 (Supplement 1): 2098.

https://doi.org/10.1182/blood-2023-190399

Published: 2023

Journal Articles

Conditioning Impacts on Regulatory T-Cells (Tregs) in the Microenvironment of AML: Observations from the Phase 1 Cynk-001-AML-001 Trial

Eunice S Wang, Hongtao Liu, Daniel N. Egan, Adrian Kilcoyne, Bhavani Stout, Natalia Ruggeri Barbaro, Cherie Daly, Siyara Kilcoyne, Robert Hariri, James McCloskey

Blood (2023) 142 (Supplement 1): 2860.

https://doi.org/10.1182/blood-2023-189508

Published: 2023

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

Maher Albitar, Andrew Ip, Andre H. Goy, Katherine Linder, Jeffrey Justin Estella, Ahmad Charifa, Wanlong Ma, Andrew L. Pecora, Jamie Koprivnikar, James McCloskey

Blood (2022) 140 (Supplement 1): 6270–6271.

https://doi.org/10.1182/blood-2022-167406

Published: 2022

Journal Articles

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

James McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen A Strickland, Amir T. Fathi, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Mark J. Levis

Blood (2022) 140 (Supplement 1): 3312–3314.

https://doi.org/10.1182/blood-2022-159680

Published: 2022

Journal Articles

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Vanessa E. Kennedy, Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, Elaine Tran, Andrew Koh, Jessica K. Altman, Naval Daver, Mark J. Levis, James McCloskey, Alexander Perl, Catherine Smith

Blood (2022) 140 (Supplement 1): 2244–2246.

https://doi.org/10.1182/blood-2022-160304

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 594–595.

https://doi.org/10.1182/blood-2022-159086

Published: 2022

Journal Articles

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Blood (2021) 138 (21): 2042–2050.

https://doi.org/10.1182/blood.2021012082

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona

Blood (2020) 136 (6): 674–683.

https://doi.org/10.1182/blood.2019004143

Published: 2020

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

NARROW

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Results of Cynk-001-AML-001: A Phase I Multi-Dose Study Evaluating the Safety, Tolerability, and Persistence of Cynk-001 in Adults with De Novo or Secondary Acute Myeloid Leukemia in Morphologic Complete Remission with Minimal Residual Disease or Relapsed/Refractory AML

Conditioning Impacts on Regulatory T-Cells (Tregs) in the Microenvironment of AML: Observations from the Phase 1 Cynk-001-AML-001 Trial

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only